iBio, Inc. (IBIO): Price and Financial Metrics

iBio, Inc. (IBIO): $0.75

0.00 (-0.44%)

POWR Rating

Component Grades








Add IBIO to Watchlist
Sign Up

Industry: Biotech




#375 of 381

in industry

IBIO Price/Volume Stats

Current price $0.75 52-week high $16.51
Prev. close $0.75 52-week low $0.36
Day low $0.74 Volume 94,063
Day high $0.76 Avg. volume 2,163,637
50-day MA $1.16 Dividend yield N/A
200-day MA $2.28 Market Cap 12.55M

IBIO Stock Price Chart Interactive Chart >


  • Growth is the dimension where IBIO ranks best; there it ranks ahead of 91.36% of US stocks.
  • IBIO's strongest trending metric is Growth; it's been moving up over the last 179 days.
  • IBIO's current lowest rank is in the Stability metric (where it is better than 1.13% of US stocks).

IBIO Stock Summary

  • With a price/sales ratio of 235.72, IBIO INC has a higher such ratio than 98.41% of stocks in our set.
  • Revenue growth over the past 12 months for IBIO INC comes in at -97.83%, a number that bests only 0.89% of the US stocks we're tracking.
  • The volatility of IBIO INC's share price is greater than that of 95.04% US stocks with at least 200 days of trading history.
  • If you're looking for stocks that are quantitatively similar to IBIO INC, a group of peers worth examining would be SERA, EMKR, BNGO, CLPT, and KLTR.
  • IBIO's SEC filings can be seen here. And to visit IBIO INC's official web site, go to www.ibioinc.com.

IBIO Valuation Summary

  • In comparison to the median Healthcare stock, IBIO's price/sales ratio is 4817.65% higher, now standing at 250.8.
  • IBIO's price/sales ratio has moved up 217.9 over the prior 165 months.

Below are key valuation metrics over time for IBIO.

Stock Date P/S P/B P/E EV/EBIT
IBIO 2023-05-23 250.8 0.9 -0.2 -0.3
IBIO 2023-05-22 255.7 0.9 -0.2 -0.3
IBIO 2023-05-19 260.7 0.9 -0.2 -0.3
IBIO 2023-05-18 260.7 0.9 -0.2 -0.3
IBIO 2023-05-17 265.6 0.9 -0.2 -0.3
IBIO 2023-05-16 255.7 0.9 -0.2 -0.3

IBIO Growth Metrics

    Its 2 year revenue growth rate is now at 114.24%.
  • The 4 year cash and equivalents growth rate now stands at -19.18%.
  • Its 2 year cash and equivalents growth rate is now at 295.5%.
Over the past 33 months, IBIO's revenue has gone up $428,000.

The table below shows IBIO's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 2.172 -42.092 -59.516
2022-06-30 2.383 -37.48 -50.391
2022-03-31 2.813 -33.203 -33.286
2021-12-31 1.635 -34.608 -28.621
2021-09-30 2.172 -32.341 -24.873
2021-06-30 2.371 -30.064 -23.467

IBIO's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • IBIO has a Quality Grade of D, ranking ahead of 5.38% of graded US stocks.
  • IBIO's asset turnover comes in at 0.017 -- ranking 375th of 681 Pharmaceutical Products stocks.
  • COLL, COCP, and IRWD are the stocks whose asset turnover ratios are most correlated with IBIO.

The table below shows IBIO's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.017 0.383 -0.256
2021-03-31 0.024 0.836 -0.331
2020-12-31 0.023 1.000 -0.317
2020-09-30 0.027 1.000 -0.273
2020-06-30 0.032 1.000 -0.231
2020-03-31 0.036 1.000 -0.271

iBio, Inc. (IBIO) Company Bio

iBio, Inc. is a biotechnology company, which engages in the development and manufacture of biotherapeutics. Its pipeline include idiopathic pulmonary fibrosis, systemic sclerosis, and scleroderma. It operates through the iBio, Inc. and iBio CDMO business segments. The company was founded on April 15, 1993 and is headquartered in New York, NY.

IBIO Latest News Stream

Event/Time News Detail
Loading, please wait...

IBIO Latest Social Stream

Loading social stream, please wait...

View Full IBIO Social Stream

Latest IBIO News From Around the Web

Below are the latest news stories about IBIO INC that investors may wish to consider to help them evaluate IBIO as an investment opportunity.

iBio Discovers New Panel of CD3 T-Cell Binding Antibodies Using its Patented AI Epitope Steering Platform

BRYAN, Texas, April 04, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announced that a presentation given today by its VP & Head of Machine Learning & Platform Technologies, Matt Greving, Ph.D., during Carterra's "Unlocking High-Throughput Biology and Drug Discovery" symposium in San Diego, CA, revealed the discovery of a panel of CD3 T-cell binding antibodies, representing an important first step for the

Yahoo | April 4, 2023

iBio Advances Anti-CCR8 Antibody Program to Preclinical In Vivo Testing

– Immuno-oncology candidate discovered using iBio’s AI epitope steering platform – – Expands Treg depletion franchise beyond IBIO-101 – BRYAN, Texas, March 31, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced the progression of its anti-CCR8 antibody immuno-oncology program into preclinical in vivo testing. CCR8, a member of the G protein-coupled receptor (“GPCR”) family, is expressed by T-re

Yahoo | March 31, 2023

7 Stocks to Sell as Banks Melt Down

Although the internet encourages you to buy the red ink, sometimes you should consider stocks to sell as just that.

Josh Enomoto on InvestorPlace | March 20, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

We're starting off the final trading day of the week with a look at the biggest pre-market stock movers worth watching on Friday!

William White on InvestorPlace | February 17, 2023

Why Is Ambrx Biopharma (AMAM) Stock Down 15% Today?

Ambrx Biopharma (AMAM) stock is falling on Friday but it's not due to any negative news released by the medical company today.

William White on InvestorPlace | February 17, 2023

Read More 'IBIO' Stories Here

IBIO Price Returns

1-mo -31.19%
3-mo -61.73%
6-mo 20.97%
1-year -87.63%
3-year -98.06%
5-year -97.97%
YTD 68.77%
2022 -96.76%
2021 -47.71%
2020 321.69%
2019 -66.80%
2018 -57.63%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!